Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sierra Believes It Can Do Better Than Gilead With JAK Inhibitor Momelotinib

Businessman comparing two documents, neutral background

Related Content

Gilead, JAKed About Cancer Research, Buys YM BioScienses

Dec 12 2012

Gilead's Late-Stage R&D Misfire Gives Respite To Competing Myelofibrosis Therapies

Nov 17 2016

AbbVie's Upadacitinib Safety Appears Improved In Largest, Longest RA Study

Apr 10 2018

Lilly Prices Olumiant For JAK Battle, But Misses Approval For Higher Dose

Jun 02 2018

Related Companies

YM BioSciences Inc.

Sierra Oncology, Inc.

Gilead Sciences, Inc.

Incyte Corporation

Pfizer Inc.

Eli Lilly and Company

AbbVie Inc.

Eli Lilly and Company

Additional Topics

Deals Commercial Business Strategies Research & Development Cancer BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window